

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Assays & screens			
Quantification of minimal residual disease in chronic lymphocytic leukemia (CLL) following hematopoietic stem cell transplant	High throughput measurement of minimal residual disease in CLL following hematopoietic stem cell transplant could improve early intervention to prevent disease relapse. In samples from patients with CLL, the approach showed higher sensitivity for minimal residual disease than a flow cytometry-based technique and did not require the use of patient-specific primers and probes. Next steps include demonstrating the applicability and sensitivity of the screening approach in an undisclosed setting.	Work unpatented; licensing status not applicable	Logan, A.C. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Dec. 12, 2011; doi:10.1073/pnas.1118357109 Contact: David B. Miklos, Stanford University School of Medicine, Stanford, Calif. e-mail: dmiklos@stanford.edu Contact: Ronald W. Davis, same affiliation as above e-mail: dbowe@stanford.edu
	SciBX 5(1); doi:10.1038/scibx.2012.26 Published online Jan. 5, 2012		